 |
市場調查報告書
商品編碼
1477925
鉅細胞病毒 (CMV) 治療市場 - 按藥物類型（纈更昔洛韋、更昔洛韋、西多福韋、膦甲酸）、應用、給藥途徑、配銷通路- 全球預測，2024 年 - 2032 年Cytomegalovirus (CMV) Treatment Market - By Drug Type (Valganciclovir, Ganciclovir, Cidofovir, Foscarnet), Application, Route of Administration, Distribution Channel - Global Forecast, 2024 - 2032 |
||||||
在醫療技術和診斷技術的進步以及人們對早期檢測和治療選擇的認知不斷提高的推動下，鉅細胞病毒（CMV）治療市場規模預計在2024 年至2032 年期間將以6.6% 的複合年成長率擴大。
由於免疫系統較弱，器官移植受者和愛滋病毒/愛滋病患者越來越容易感染鉅細胞病毒。隨著全球器官移植數量的不斷增加以及愛滋病毒/愛滋病病例的不斷上升，對有效的鉅細胞病毒治療方案的需求不斷增加。根據 UNOS（器官共享聯合網路）的數據，2022 年，進行了超過 42,800 例器官移植，創下了新的年度記錄。
醫療保健提供者也認知到在這個脆弱患者群體中預防和管理鉅細胞病毒感染的重要性，以改善臨床結果並降低併發症的風險。因此，越來越需要創新療法和治療策略，以解決器官移植和愛滋病毒/愛滋病患者中鉅細胞病毒感染帶來的獨特挑戰，從而推動市場成長。
CMV治療市場根據藥物類型、配銷通路、給藥途徑、應用和區域進行分類。
西多福韋藥物類型領域的行業規模預計到 2032 年將成長 6.8%，因為該藥物抑制病毒 DNA 複製，使其成為對抗 CMV 感染的有效抗病毒藥物。廣譜活性和良好的安全性使西多福韋成為 CMV 治療的首選，特別是對於免疫功能低下的患者。此外，延長半衰期、減少給藥頻率、提高患者依從性和便利性等好處將促進該細分市場的成長。
由於線上藥局提供的便利性、可及性和自由裁量權，電子商務平台配銷通路領域的鉅細胞病毒治療市場到 2032 年可能會出現 6.5% 的複合年成長率。電子商務平台通常提供廣泛的產品選擇、有競爭力的價格和送貨上門的服務，進一步增強了對消費者的吸引力。線上購買的成長趨勢，加上網路和智慧型手機技術的日益普及，也推動了電子商務在醫療保健領域的擴張。
在醫療保健支出增加、對傳染病的認知不斷提高以及醫療保健基礎設施不斷擴大的推動下，亞太地區 CMV 治療市場預計在 2024 年至 2032 年期間複合年成長率為 7%。在龐大的患者群體和對有效 CMV 治療方案不斷成長的需求的推動下，中國、印度和日本等國家預計將引領市場擴張。此外，旨在改善醫療保健可近性和負擔能力的政府措施以及有利的監管政策正在為該地區的行業成長創造有利的環境。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 鉅細胞病毒感染率上升
- 不斷提高的認知和新藥物療法的引入
- 愛滋病患者傳染病病率高
- CMV 視網膜炎和先天性 CMV 感染患者數量激增
- 產業陷阱與挑戰
- 與鉅細胞病毒藥物相關的不良反應
- 成長動力
- 成長潛力分析
- 監管環境
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司矩陣分析
- 競爭定位矩陣
- 戰略儀錶板
第 5 章：市場估計與預測：按藥物類型，2018 - 2032
- 主要趨勢
- 纈更昔洛韋
- 更昔洛韋
- 西多福韋
- 膦甲酸
- 其他藥物種類
第 6 章：市場估計與預測：按應用分類，2018 年 - 2032 年
- 主要趨勢
- 幹細胞移植
- 器官移植
- 先天性鉅細胞病毒感染
- 其他應用
第 7 章：市場估計與預測：按管理途徑，2018 年 - 2032 年
- 主要趨勢
- 口服
- 靜脈
第 8 章：市場估計與預測：按配銷通路，2018 年 - 2032 年
- 主要趨勢
- 醫院藥房
- 零售藥局
- 電子商務
第 9 章：市場估計與預測：按地區分類，2018 年 - 2032 年
- 主要動向：按地區
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
- 亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 中東和非洲其他地區
第 10 章：公司簡介
- Chimerix, Inc.
- Clinigen Group PLC
- F. Hoffmann-La Roche Ltd
- Fresenius Kabi
- Genentech Inc.
- Gilead Sciences, Inc.
- Merck & Co. Inc
- Mylan N.V
- Pfizer, Inc.
- Takeda Pharmaceuticals
- Teva Pharmaceuticals Inc
- Thermo Fisher Scientific Inc.
Cytomegalovirus (CMV) Treatment Market size is expected to expand at 6.6% CAGR during 2024-2032, driven by advancements in medical technology and diagnostic techniques along with the rising awareness about early detection and treatment options.
Organ transplant recipients and individuals with HIV/AIDS have grown susceptible to CMV infections due to their weakened immune systems. With the increasing number of organ transplantations performed globally and the rising prevalence of HIV/AIDS cases, the demand for effective CMV treatment options is on the rise. As per UNOS (United Network for Organ Sharing), in 2022, over 42,800 organ transplants were performed, setting a new annual record.
Healthcare providers are also recognizing the importance of preventing and managing CMV infections in this vulnerable patient population to improve clinical outcomes and reduce the risk of complications. Consequently, there is a growing need for innovative therapies and treatment strategies tailored to address the unique challenges posed by CMV infection in organ transplant and HIV/AIDS patients, thereby driving the market growth.
The CMV treatment market is classified based on drug type, distribution channel, route of administration, application, and region.
The industry size from the cidofovir drug type segment is expected to record 6.8% growth rate till 2032, as the drug inhibits viral DNA replication, making it an effective antiviral agent against CMV infections. The broad-spectrum activity and favorable safety profile have positioned cidofovir as a preferred choice for CMV treatment, particularly in immunocompromised patients. Furthermore, benefits like extended half-life to offer less frequent dosing for enhancing patient compliance and convenience will add to the segment growth.
Cytomegalovirus treatment market from the E-commerce platform distribution channel segment may witness 6.5% CAGR up to 2032, owing to the convenience, accessibility, and discretion offered by online pharmacies. E-commerce platforms often provide a wide range of product choices, competitive pricing, and doorstep delivery, further enhancing their appeal to consumers. The growing trend of online purchasing, coupled with the increasing penetration of internet and smartphone technologies has also fueled the expansion of e-commerce in the healthcare sector.
Asia Pacific CMV treatment market is poised to depict 7% CAGR during 2024-2032, driven by increasing healthcare expenditure, rising awareness about infectious diseases, and expanding healthcare infrastructure. Countries, such as China, India, and Japan are expected to lead the market expansion, fueled by large patient population and the growing demand for effective CMV treatment options. Furthermore, government initiatives aimed at improving healthcare accessibility and affordability along with favorable regulatory policies are creating conducive environments for industry growth in the region.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Base estimates & calculations
- 1.3 Data collection
- 1.4 Forecast parameter
- 1.5 Data validation
- 1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
- 1.6.2.1 Paid sources
- 1.6.2.2 Public sources
Chapter 2 Executive Summary
- 2.1 Industry 360 degree synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rise in the prevalence of cytomegalovirus infection
- 3.2.1.2 Growing awareness and introduction of new drug therapies
- 3.2.1.3 High prevalence of infectious diseases among AIDS patients
- 3.2.1.4 Upsurge in patient pool of CMV retinitis and congenital CMV infection
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Adverse effects associated with cytomegalovirus drugs
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutes
- 3.5.5 Industry rivalry
- 3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Competitive positioning matrix
- 4.4 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2018 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Valganciclovir
- 5.3 Ganciclovir
- 5.4 Cidofovir
- 5.5 Foscarnet
- 5.6 Other drug types
Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Stem cell transplantation
- 6.3 Organ transplantation
- 6.4 Congenital CMV infection
- 6.5 Other applications
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Oral
- 7.3 Intravenous
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospital pharmacies
- 8.3 Retail pharmacies
- 8.4 E-commerce
Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)
- 9.1 Key trends, by region
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 Chimerix, Inc.
- 10.2 Clinigen Group PLC
- 10.3 F. Hoffmann-La Roche Ltd
- 10.4 Fresenius Kabi
- 10.5 Genentech Inc.
- 10.6 Gilead Sciences, Inc.
- 10.7 Merck & Co. Inc
- 10.8 Mylan N.V
- 10.9 Pfizer, Inc.
- 10.10 Takeda Pharmaceuticals
- 10.11 Teva Pharmaceuticals Inc
- 10.12 Thermo Fisher Scientific Inc.
